These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
273 related articles for article (PubMed ID: 27053601)
1. Synthesis and characterization of a disubstituted piperazine derivative with T-type channel blocking action and analgesic properties. Pudukulatham Z; Zhang FX; Gadotti VM; M'Dahoma S; Swami P; Tamboli Y; Zamponi GW Mol Pain; 2016; 12():. PubMed ID: 27053601 [TBL] [Abstract][Full Text] [Related]
2. Effect of the T-type channel blocker KYS-05090S in mouse models of acute and neuropathic pain. M'Dahoma S; Gadotti VM; Zhang FX; Park B; Nam JH; Onnis V; Balboni G; Lee JY; Zamponi GW Pflugers Arch; 2016 Feb; 468(2):193-9. PubMed ID: 26354962 [TBL] [Abstract][Full Text] [Related]
3. Design and synthesis of novel anti-hyperalgesic agents based on 6-prenylnaringenin as the T-type calcium channel blockers. Du Nguyen H; Okada T; Kitamura S; Yamaoka S; Horaguchi Y; Kasanami Y; Sekiguchi F; Tsubota M; Yoshida S; Nishikawa H; Kawabata A; Toyooka N Bioorg Med Chem; 2018 Aug; 26(15):4410-4427. PubMed ID: 30031654 [TBL] [Abstract][Full Text] [Related]
4. Synthesis and T-type calcium channel blocking activity of novel diphenylpiperazine compounds, and evaluation of in vivo analgesic activity. Kam YL; Rhee HK; Rhim H; Back SK; Na HS; Choo HY Bioorg Med Chem; 2010 Aug; 18(16):5938-44. PubMed ID: 20659804 [TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological evaluation of novel N3-substituted dihydropyrimidine derivatives as T-type calcium channel blockers and their efficacy as analgesics in mouse models of inflammatory pain. Teleb M; Zhang FX; Huang J; Gadotti VM; Farghaly AM; AboulWafa OM; Zamponi GW; Fahmy H Bioorg Med Chem; 2017 Mar; 25(6):1926-1938. PubMed ID: 28233679 [TBL] [Abstract][Full Text] [Related]
9. 5beta-reduced neuroactive steroids are novel voltage-dependent blockers of T-type Ca2+ channels in rat sensory neurons in vitro and potent peripheral analgesics in vivo. Todorovic SM; Pathirathna S; Brimelow BC; Jagodic MM; Ko SH; Jiang X; Nilsson KR; Zorumski CF; Covey DF; Jevtovic-Todorovic V Mol Pharmacol; 2004 Nov; 66(5):1223-35. PubMed ID: 15280444 [TBL] [Abstract][Full Text] [Related]
10. Effect of ABT-639 on Cav3.2 channel activity and its analgesic actions in mouse models of inflammatory and neuropathic pain. Antunes FTT; Huang S; Chen L; Zamponi GW Eur J Pharmacol; 2024 Mar; 967():176416. PubMed ID: 38342359 [TBL] [Abstract][Full Text] [Related]
11. NMP-7 inhibits chronic inflammatory and neuropathic pain via block of Cav3.2 T-type calcium channels and activation of CB2 receptors. Berger ND; Gadotti VM; Petrov RR; Chapman K; Diaz P; Zamponi GW Mol Pain; 2014 Dec; 10():77. PubMed ID: 25481027 [TBL] [Abstract][Full Text] [Related]
12. Structure-activity study and analgesic efficacy of amino acid derivatives as N-type calcium channel blockers. Seko T; Kato M; Kohno H; Ono S; Hashimura K; Takimizu H; Nakai K; Maegawa H; Katsube N; Toda M Bioorg Med Chem Lett; 2001 Aug; 11(16):2067-70. PubMed ID: 11514140 [TBL] [Abstract][Full Text] [Related]
13. Synthesis and evaluation of alpha,alpha'-disubstituted phenylacetate derivatives for T-type calcium channel blockers. Lee HK; Lee YS; Roh EJ; Rhim H; Lee JY; Shin KJ Bioorg Med Chem Lett; 2008 Aug; 18(15):4424-7. PubMed ID: 18625556 [TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological evaluation of 1-(2-hydroxy-3-phenyloxypropyl)piperazine derivatives as T-type calcium channel blockers. Park JE; Ji WK; Jang JW; Pae AN; Choi K; Choi KH; Kang J; Roh EJ Bioorg Med Chem Lett; 2013 Mar; 23(6):1887-90. PubMed ID: 23395659 [TBL] [Abstract][Full Text] [Related]
15. T-type calcium channel inhibition underlies the analgesic effects of the endogenous lipoamino acids. Barbara G; Alloui A; Nargeot J; Lory P; Eschalier A; Bourinet E; Chemin J J Neurosci; 2009 Oct; 29(42):13106-14. PubMed ID: 19846698 [TBL] [Abstract][Full Text] [Related]
16. Free radical signalling underlies inhibition of CaV3.2 T-type calcium channels by nitrous oxide in the pain pathway. Orestes P; Bojadzic D; Lee J; Leach E; Salajegheh R; Digruccio MR; Nelson MT; Todorovic SM J Physiol; 2011 Jan; 589(Pt 1):135-48. PubMed ID: 21059758 [TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological evaluation of pyrrolidine-based T-type calcium channel inhibitors for the treatment of neuropathic pain. Yang HK; Son WS; Lim KS; Kim GH; Lim EJ; Gadhe CG; Lee JY; Jeong KS; Lim SM; Pae AN J Enzyme Inhib Med Chem; 2018 Dec; 33(1):1460-1471. PubMed ID: 30231778 [TBL] [Abstract][Full Text] [Related]
18. Blockade of T-type calcium channels by 6-prenylnaringenin, a hop component, alleviates neuropathic and visceral pain in mice. Sekiguchi F; Fujita T; Deguchi T; Yamaoka S; Tomochika K; Tsubota M; Ono S; Horaguchi Y; Ichii M; Ichikawa M; Ueno Y; Koike N; Tanino T; Nguyen HD; Okada T; Nishikawa H; Yoshida S; Ohkubo T; Toyooka N; Murata K; Matsuda H; Kawabata A Neuropharmacology; 2018 Aug; 138():232-244. PubMed ID: 29913186 [TBL] [Abstract][Full Text] [Related]
19. Synthesis and evaluation of aminobenzothiazoles as blockers of N- and T-type calcium channels. Sairaman A; Cardoso FC; Bispat A; Lewis RJ; Duggan PJ; Tuck KL Bioorg Med Chem; 2018 Jul; 26(11):3046-3059. PubMed ID: 29622412 [TBL] [Abstract][Full Text] [Related]